Document is current
Any future updates will be listed below
-
Authors
Wolf, Gernot https://orcid.org/0000-0002-3943-8662
Leippe, Philipp https://orcid.org/0000-0002-1109-5610
Onstein, Svenja https://orcid.org/0000-0003-3309-1474
Goldmann, Ulrich https://orcid.org/0000-0003-1120-6912
Frommelt, Fabian https://orcid.org/0000-0003-3666-8005
Teoh, Shao Thing https://orcid.org/0000-0002-5938-258X
Girardi, Enrico https://orcid.org/0000-0003-3508-2723
Wiedmer, Tabea https://orcid.org/0000-0002-0355-9315
Superti-Furga, Giulio https://orcid.org/0000-0002-0570-1768
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative 2 (777372)
Austrian Academy of Sciences
- License Information
-
More Information
Article History
Received: 17 October 2024
Revised: 28 March 2025
Accepted: 31 March 2025
First Online: 12 May 2025
Disclosure and competing interests statement
: GS-F is co-founder and owns shares of Solgate GmbH, an SLC-focused company. EG is the CSO of Solgate GmbH.
